Biosimilars could deliver over a billion dollars in savings per year to the Canadian health care system.

Governments can use savings to provide more patients with access to more treatments.

2.1%

of paid beneficiaries accounted for

38.8% of total spending³

In 2018, **three of the top five** most costly medications in Canada were biologics, despite the availability of lower-cost, safe biosimilars available to Canadians.⁴

\$808M

Potential savings based on OECD high uptake 2021

\$346M

Potential savings based on OECD moderate uptake 2021

\$94M

Actual 2018 savings

Alberta and British Columbia have already **discovered** the potential saving from biosimilars.

"By using biosimilars in B.C., we will be putting about **\$96.6 million back into health care** over the next three years." Adrian Dix, Minister of Health B.C.⁵

In Alberta, biologic drugs cost more than \$238 million in the 2018-19 fiscal year, switching to biosimilars will save between \$227 million and \$380 million over the next four years.⁶



¹ Biologics in Canada. Part 2: Biosimilar Savings, 2018, https://www.canada.ca/en/patented-medicine-prices-review/services/reports-studies/biologics-part2-biosimilar-savings2018.html 2 Biologics in Canada. Part 2: Biosimilar Savings, 2018, https://www.canada.ca/en/patented-medicine-prices-review/services/reports-studies/biologics-part2-biosimilar-savings2018.html 2 Biologics in Canada. Public drug dollars-spent on-high-cost-drugs. Glauser portion-of-canadas-public-drug-dollars-spent-on-high-cost-drugs 4 Current and Prospective Utilization of Innovator of Biologics and Biosimilars in Ontario, ODPRN, 2020, https://odprn.ca/wp-content/uploads/2020/01/Utilization-of-Innovator-Biologics-and

⁵ B.C. expands biosimilars program, 2019, https://news.gov.bc.ca/releases/2019HLTH0125-0017